Literature DB >> 16517843

Analysis of mutations within the 5' untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in hepatitis C virus-infected patients in India.

Romi Gupta1, Murugan Subramani, Mohammed N Khaja, Chandra Madhavi, Swagata Roy, Chittoor M Habibullah, Saumitra Das.   

Abstract

Mutations in several subgenomic regions have been implicated in influencing response to interferon therapy; however, a comprehensive picture of Indian patients was lacking. Based on the viral load and clinical factors, 10 out of 15 patients were found to be complete responders, whereas 5 patients were nonresponders. The pretreatment viral RNA load of the patients was found to be between 5.20 and 6.13 log10 IU/ml, which eventually fell to 2.77 log10 IU/ml after 24 weeks of treatment, whereas in the case of nonresponders, the average was 5.38 log10 IU/ml. In order to study the influence of the hepatitis C virus genotype on the response to interferon therapy, the 5' untranslated region sequences of the samples were analyzed, which showed that genotype 3 patients responded better than genotype 1 patients. Additionally, the mutations in the interferon sensitivity-determining region (ISDR) of the NS5A protein and the double-stranded RNA-activated protein kinase-eukaryotic initiation factor 2 alpha phosphorylation homology domain (PePHD) of the E2 envelope protein, before and after treatment, were compared with nonresponder prototype J. Although, no clear correlation was found in the case of the mutated ISDR, some significant changes in residues were observed in the PePHD region, which could be helpful in understanding the molecular basis of resistance to therapy. Interestingly, analysis of the quasispecies variations showed a change in genotype in one sample during treatment, which might have contributed to the resistance. The results suggest that the mutations in different regions of the viral genome might have a concerted effect on the response to interferon therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517843      PMCID: PMC1393096          DOI: 10.1128/JCM.44.3.709-715.2006

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy.

Authors:  K Chayama; F Suzuki; A Tsubota; M Kobayashi; Y Arase; S Saitoh; Y Suzuki; N Murashima; K Ikeda; N Takahashi; M Kinoshita; H Kumada
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

2.  Hepatitis C virus infection in the general population: a community-based study in West Bengal, India.

Authors:  Abhijit Chowdhury; Amal Santra; Susmita Chaudhuri; Gopal Krishna Dhali; Sujit Chaudhuri; Satya Gopal Maity; Trailokya Nath Naik; Sujit Kumar Bhattacharya; Debendra Nath Guha Mazumder
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

3.  Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.

Authors:  Catherine Gaudy; Marie Lambelé; Alain Moreau; Pascal Veillon; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

4.  Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India.

Authors:  Sompal Singh; Veena Malhotra; Shiv Kumar Sarin
Journal:  Indian J Med Res       Date:  2004-04       Impact factor: 2.375

5.  Phylogenetic conservation of the stem-loop III structure of the 5' untranslated region of Hepatitis C virus RNA among natural variants in samples collected from Southern India.

Authors:  S Bhattacharyya; K Mapa; S Prabhavathi; S R Sudhamani; P K Menon; K P J John; C Shivaram; S Amarnath; S Das
Journal:  Arch Virol       Date:  2004-01-29       Impact factor: 2.574

6.  Comparison of hepatitis C virus genotyping by 5' noncoding region- and core-based reverse transcriptase PCR assay with sequencing and use of the assay for determining subtype distribution in India.

Authors:  Kavita S Lole; Jyotsna A Jha; Sandhya P Shrotri; Badri N Tandon; V G Mohan Prasad; Vidya A Arankalle
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

7.  Treatment of hepatitis C virus infection in patients of northern India.

Authors:  Sidhartha Hazari; Subrat Kumar Panda; Siddharth Datta Gupta; Yogesh Batra; Rajbir Singh; Subrat Kumar Acharya
Journal:  J Gastroenterol Hepatol       Date:  2004-09       Impact factor: 4.029

Review 8.  The nature of interferon-alpha resistance in hepatitis C virus infection.

Authors:  Jean-Michel Pawlotsky
Journal:  Curr Opin Infect Dis       Date:  2003-12       Impact factor: 4.915

Review 9.  Current and future therapy for chronic hepatitis C virus liver disease.

Authors:  G Lake-Bakaar
Journal:  Curr Drug Targets Infect Disord       Date:  2003-09

10.  Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response.

Authors:  C Sarrazin; I Kornetzky; B Rüster; J H Lee; B Kronenberger; K Bruch; W K Roth; S Zeuzem
Journal:  Hepatology       Date:  2000-06       Impact factor: 17.425

View more
  8 in total

1.  Frequency of nucleotide sequence variations in the internal ribosome entry site region of hepatitis C virus RNA isolated from responding and non-responding patients with hepatitis C virus genotype 3 infection.

Authors:  Anzar Ashraf; Anita Chakravarti; Priyamvada Roy; Premashish Kar; Oves Siddiqui
Journal:  Virusdisease       Date:  2016-08-06

2.  Influence of quasispecies on virological responses and disease severity in patients with chronic hepatitis C.

Authors:  Deepak Kumar; Abdul Malik; Mohammad Asim; Anita Chakravarti; Rakha-H Das; Premashis Kar
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

Review 3.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

4.  Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein.

Authors:  Ijaz Ali; Sanaullah Khan; Sobia Attaullah; Shahid Niaz Khan; Jabbar Khan; Sami Siraj; Aqib Iqbal; Zahoor A Swati; Muhammad Idrees
Journal:  Virol J       Date:  2011-05-25       Impact factor: 4.099

5.  A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data.

Authors:  Alicia Amadoz; Fernando González-Candelas
Journal:  Evol Bioinform Online       Date:  2015-02-23       Impact factor: 1.625

6.  Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.

Authors:  P Muñoz de Rueda; J Casado; R Patón; D Quintero; A Palacios; A Gila; R Quiles; J León; A Ruiz-Extremera; J Salmerón
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

Review 7.  Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

Authors:  Ahmed El-Shamy; Hak Hotta
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

8.  Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.

Authors:  Nathan A Cannon; Maureen J Donlin; Xiaofeng Fan; Rajeev Aurora; John E Tavis
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.